Active	Status	Sponsor type	Region	Phase	Filter
8 Active 2 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Passamonti, Francesco
MYLOX-1, NCT04679870 / 2020-003087-45: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis	Active, not recruiting	2	21	Europe, US, RoW	GB2064	Galecto Biotech AB, OPIS s.r.l	Myelofibrosis	12/23	06/26
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myelofibrosis First patient dosed as a monotherapy in patients with 2L myelofibrosis Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis	Active, not recruiting	2	112	Europe, US, RoW	Selinexor, Physician's Choice Treatment	Karyopharm Therapeutics Inc	Myelofibrosis	01/25	01/25
Passamonti, Francescp
No trials found